Zobrazeno 1 - 10
of 90
pro vyhledávání: '"Mark, Bartholomä"'
Autor:
Caroline Burgard, Florian Rosar, Elena Larsen, Fadi Khreish, Johannes Linxweiler, Robert J. Marlowe, Andrea Schaefer-Schuler, Stephan Maus, Sven Petto, Mark Bartholomä, Samer Ezziddin
Publikováno v:
Cancer Imaging, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Positron emission tomography/computed tomography (PET/CT) using prostate-specific membrane antigen (PSMA)-targeted radiotracers labeled with zirconium-89 (89Zr; half-life ~ 78.41 h) showed promise in localizing biochemical recurre
Externí odkaz:
https://doaj.org/article/03c17f9cf9d84758a0e74cfd128f0a03
Autor:
Florian Rosar, Caroline Burgard, Scott David, Robert J. Marlowe, Mark Bartholomä, Stephan Maus, Sven Petto, Fadi Khreish, Andrea Schaefer-Schuler, Samer Ezziddin
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Candidates for prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) of metastatic castration-resistant prostate cancer (mCRPC) frequently have “mismatch” lesions with pronounced 18-fluorodeoxyglucose ([18F]FDG) bu
Externí odkaz:
https://doaj.org/article/f9053057e4e4460dbb99f656e62bc2b4
Autor:
Florian Rosar, Caroline Burgard, Elena Larsen, Fadi Khreish, Robert J. Marlowe, Andrea Schaefer-Schuler, Stephan Maus, Sven Petto, Mark Bartholomä, Samer Ezziddin
Publikováno v:
Cancer Imaging, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background The state-of-the-art method for imaging men with biochemical recurrence of prostate cancer (BCR) is prostate-specific membrane antigen (PSMA)-targeted positron emission tomography/computed tomography (PET/CT) with tracers containi
Externí odkaz:
https://doaj.org/article/70e3e288133843f68a4f03ac95be4f7e
Autor:
Caroline Burgard, Jakob Engler, Arne Blickle, Mark Bartholomä, Stephan Maus, Andrea Schaefer-Schuler, Fadi Khreish, Samer Ezziddin, Florian Rosar
Publikováno v:
Frontiers in Medicine, Vol 10 (2024)
PurposeThe value of [18F]fluorodeoxyglucose ([18F]FDG) PET/CT in monitoring prostate-specific membrane antigen (PSMA) targeted radioligand therapy (RLT) is still unclear. The aim of this study was to identify appropriate prognostic dynamic parameters
Externí odkaz:
https://doaj.org/article/c1f82cdc6cb74ef7a564458e3ac9f5fa
Autor:
Florian Rosar, Niklas Schön, Hendrik Bohnenberger, Mark Bartholomä, Tobias Stemler, Stephan Maus, Fadi Khreish, Samer Ezziddin, Andrea Schaefer-Schuler
Publikováno v:
EJNMMI Physics, Vol 8, Iss 1, Pp 1-15 (2021)
Abstract Background Dosimetry is of high importance for optimization of patient-individual PSMA-targeted radioligand therapy (PSMA-RLT). The aim of our study was to evaluate and compare the feasibility of different approaches of image-based absorbed
Externí odkaz:
https://doaj.org/article/457c2d32be85495990fec9585f9b8948
Autor:
Florian Rosar, Kalle Ribbat, Martin Ries, Johannes Linxweiler, Mark Bartholomä, Stephan Maus, Mathias Schreckenberger, Samer Ezziddin, Fadi Khreish
Publikováno v:
EJNMMI Research, Vol 10, Iss 1, Pp 1-10 (2020)
Abstract Background PSMA-targeted radioligand therapy (PSMA-RLT) yielded impressive results in the metastasized castration-resistant prostate carcinoma (mCRPC) setting. High expression of PSMA is essential for successful PSMA-RLT. However, some patie
Externí odkaz:
https://doaj.org/article/93fc3c2b704f43bcbaa407c378b121b4
Autor:
Cordula A. Jilg, Kathrin Reichel, Christian Stoykow, H. Christian Rischke, Mark Bartholomä, Vanessa Drendel, Moritz von Büren, Wolfgang Schultze-Seemann, Philipp T. Meyer, Michael Mix
Publikováno v:
EJNMMI Research, Vol 10, Iss 1, Pp 1-13 (2020)
Abstract Purpose Identification of suspicious PSMA-PET/CT-positive lymph node (LN) metastases (LNM) from prostate cancer (PCa) during lymphadenectomy (LA) is challenging. We evaluated an 111In-labelled PSMA ligand (DKFZ-617, referred to as [111In]PSM
Externí odkaz:
https://doaj.org/article/3caf1d9e4cfc4126b623fb2a44837206
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-16 (2019)
Abstract Background Immunogenic radiotherapy (RT) can act synergistically with immune checkpoint blockers (ICBs). However, alternatives are needed for non-responding patients and those with pre-existing or ICB-induced autoimmune symptoms. Combination
Externí odkaz:
https://doaj.org/article/e457fde1ed04482cb15845f9bd6b08c0
Autor:
Florian Rosar, Fadi Khreish, Robert J. Marlowe, Andrea Schaefer-Schuler, Caroline Burgard, Stephan Maus, Sven Petto, Mark Bartholomä, Samer Ezziddin
Rationale In patients with biochemical recurrence of prostate cancer (BCR), preliminary data suggest that prostate-specific membrane antigen (PSMA) ligand radiotracers labeled with zirconium-89 (89Zr; half-life ~ 78.41 h), which allow imaging ≥ 24
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::033538212d019034e71af24ca01f5920
Autor:
Caroline Burgard, Florian Rosar, Robert J. Marlowe, Mark Bartholomä, Sebastian Dewes, Andrea Schaefer-Schuler, Johannes Linxweiler, Fadi Khreish, Samer Ezziddin
Publikováno v:
Cancers; Volume 15; Issue 9; Pages: 2592
“Tumor sink effects”, decreased physiological uptake of radiopharmaceuticals due to sequestration by a tumor, may impact radioligand therapy (RLT) toxicity and dosing. We investigated these effects with prostate-specific membrane antigen (PSMA)-t